Passez à l'illimité avec Magzter GOLD

Passez à l'illimité avec Magzter GOLD

Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement

$149.99
 
$74.99/Année

Essayer OR - Gratuit

How Asia is Addressing Mental Health Issues?

BioSpectrum Asia

|

October 2024

Nearly one billion people globally live with mental health conditions, and about 260 million of them reside in the World Health Organization WHO) South-East Asia Region. Governments across Asia are ramping up efforts to combat the rising mental health crisis. As October 10 will be observed as World Mental Health Day, we take a look at the region's focus on policy reforms to address the growing burden of mental healthcare across Asia.

- Ayesha Siddiqui

How Asia is Addressing Mental Health Issues?

Mental health issues are well-documented, affecting nearly one billion people worldwide, with approximately 260 million residing in the WHO South-East Asia Region. Insufficient investment in mental health services and the healthcare workforce has led to significant treatment gaps in the region, a situation further worsened by the COVID-19 pandemic. Global estimates indicate the WHO South-East Asia Region accounts for around 27 per cent of all cases of depression and 23 per cent of all cases of anxiety.

Despite its inclusion in the Sustainable Development Goals (SDGs), only 2 per cent of total government health expenditure and 1 per cent of global development assistance for health are dedicated to mental health, according to the WHO’s Mental Health Atlas 2020.

Mental illness presents a significant health and socioeconomic burden, accounting for over 20 per cent of total Years Lived with Disability (YLDs) and 9.3 per cent of Disability-Adjusted Life Years (DALYs) in the Asia-Pacific region. As per a report by The Royal Australian and New Zealand College of Psychiatrists (2016), even advanced economies like Australia and New Zealand face GDP deficits of 3.5 per cent and 5 per cent, respectively, linked to mental illness. Furthermore, it is estimated that by 2030, mental illness will result in a loss of $11 trillion in economic growth for India and China alone, according to a report ‘Provision for Supporting People with Mental Illness: A Comparison of 15 Asia-Pacific Countries,’ prepared by The Economist Intelligence Unit (EIU) and sponsored by Janssen Asia Pacific.

To address these growing concerns, policymakers and health systems across the region are taking a note. Various countries have developed national strategic plans and made investments to strengthen mental healthcare.

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size